link for complete article- Forbes.comMorgan Stanley reiterated an "underweight" rating on Elan (nyse: ELN - news - people ), saying considerable uncertainty still exists around the future of Tysabri, the company's multiple sclerosis treatment.
"We still believe there is significant risk that Tysabri never returns to the market," Morgan Stanley said. The research firm said Elan and partner Biogen Idec have to conduct long-term studies to get the product back on the market, and that if the product does return, safety concerns may minimize its impact on earnings.
